<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148029</url>
  </required_header>
  <id_info>
    <org_study_id>F0995-R</org_study_id>
    <nct_id>NCT02148029</nct_id>
  </id_info>
  <brief_title>Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome</brief_title>
  <acronym>EFFORT2</acronym>
  <official_title>Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland, College Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite standard care, 25%-50% of patients with clots in the deep veins of the arms and legs&#xD;
      progress to chronic post-clot problems resulting in significant disability, loss of&#xD;
      productivity, and healthcare costs. Reverse flow in the veins from an organizing clot is the&#xD;
      primary cause of post-clot problems. Veins with early clot breakdown have a lower incidence&#xD;
      of reverse flow. The investigators have observed that clot breakdown is enhanced by increased&#xD;
      blood flow and that moderate arm and leg exercise result in increased venous blood flow.&#xD;
      Hence, the investigators predict that a supervised exercise program in patients with deep&#xD;
      vein clots could increase leg vein blood flow, accelerate clot breakdown, and decrease the&#xD;
      risk of post clot problems. The primary hypothesis is that increased blood flow across the&#xD;
      clot (induced by supervised exercise) will increase clot breakdown and decrease severity of&#xD;
      post clot problems. The investigators are conducting a randomized clinical trial of standard&#xD;
      therapy compared to progressive exercise training in patients with leg deep vein clots.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard anticoagulation therapy for acute deep vein thrombosis (DVT) reflects the current&#xD;
      short term focus on preventing pulmonary embolism (PE) and recurrent DVT. Despite standard&#xD;
      care, 25% to 50% of patients with DVT progress to the chronic post-thrombotic syndrome (PTS)&#xD;
      resulting in significant disability, loss of productivity, and healthcare costs. The&#xD;
      investigators postulate that a supervised exercise program in patients with acute DVT could&#xD;
      increase lower extremity venous flow, accelerate thrombus resolution, and thereby decrease&#xD;
      the risk of PTS. If the patient is unable to perform exercises, NMES (neuromuscular&#xD;
      electrical stimulation) will be used to induce contraction of the muscles of the lower&#xD;
      extremities.&#xD;
&#xD;
      Aim 1 will test whether a 3-month exercise program has long-term clinical benefits in acute&#xD;
      DVT. The primary outcome measures will be Villalta score for PTS and VEINS-QOL score (Venous&#xD;
      Insufficiency Epidemiological and Economic Study-QOL) for venous quality of life at 2 years&#xD;
      of follow-up. Aim 2 will evaluate whether exercise therapy in patients with acute DVT&#xD;
      enhances thrombus resolution. Aim 3 will assess the relationship between PTS, venous&#xD;
      hemodynamics and exercise capacity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2014</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post Thrombotic Syndrome (Villalta Score)</measure>
    <time_frame>2 years</time_frame>
    <description>Post Thrombotic Syndrome (Villalta Score)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of LIfe (SF 36, VEINS-QOL)</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of LIfe (SF 36, VEINS-QOL)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Acute Deep Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care: anticoagulation, compression &amp; ad-lib ambulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard care + Interventional Exercise therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Upper and Lower extremity exercise</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Standard care: anticoagulation, compression &amp; ad-lib ambulation</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute Lower Extremity DVT&#xD;
&#xD;
          -  Documented by ultrasound, CT/MR venogram, or conventional venogram&#xD;
&#xD;
          -  Documented within 4 weeks of onset of symptoms&#xD;
&#xD;
          -  Age 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peripheral arterial disease (disabling claudication, rest pain, tissue loss) with&#xD;
             ABI&lt;0.5&#xD;
&#xD;
          -  Immediate need for thrombolysis/thrombectomy&#xD;
&#xD;
          -  DVT involving the IVC&#xD;
&#xD;
          -  Contraindication to anticoagulation&#xD;
&#xD;
          -  Contraindications to exercise training&#xD;
&#xD;
          -  Medical illness interfering with evaluation/follow-up&#xD;
&#xD;
          -  Life expectancy &lt;2 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to walk&#xD;
&#xD;
          -  Hemodynamically significant PE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brajesh K Lal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep vein thrombosis</keyword>
  <keyword>Post thrombotic syndrome</keyword>
  <keyword>Thrombus resolution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

